| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
REDV TFA targets integrin alpha4beta1 (also known as VLA-4), a cell surface receptor that mediates cell-cell and cell-extracellular matrix interactions. By binding to integrin alpha4beta1, the peptide promotes cell adhesion. It is the minimal active sequence within the CS5 site of the fibronectin IIICS region. This peptide is a valuable tool for studying integrin-mediated cell adhesion, migration, and signaling.
|
|---|---|
| ln Vitro |
In vitro, REDV TFA mediates adhesion to the IIICS region of plasma fibronectin by binding to integrin alpha4beta1. The peptide can be used to promote cell attachment when immobilized on surfaces. It is utilized in various biochemical studies to investigate cell adhesion mechanisms. It is also used as a coating material for tissue engineering scaffolds.
|
| Enzyme Assay |
A cell-free binding assay for REDV TFA can be performed using surface plasmon resonance (SPR). Recombinant integrin alpha4beta1 protein is immobilized on a sensor chip. Increasing concentrations (0.1-100 uM) of REDV TFA are flowed over the chip. Association and dissociation rates are measured, and the Kd value is calculated. Alternatively, an ELISA-based assay can be used: plates are coated with REDV peptide, and alpha4beta1 integrin-Fc fusion protein is added in the presence of varying concentrations of competitor peptide. Binding is detected with an anti-Fc-HRP antibody.
|
| Cell Assay |
REDV TFA is used in cell adhesion assays. Integrin alpha4beta1-expressing cells (e.g., Jurkat T cells or hematopoietic stem cells) are resuspended in serum-free medium. 96-well plates are pre-coated with REDV TFA (10-100 ug/mL) in PBS overnight at 4degC and then blocked with 1% BSA. Cells (1×10⁵ cells/well) are added and allowed to adhere for 30-60 min at 37degC. Non-adherent cells are washed away. Adherent cells are quantified by crystal violet staining (absorbance at 595 nm) or by measuring endogenous alkaline phosphatase activity. For inhibition studies, cells are pre-incubated with an anti-alpha4beta1 antibody or a soluble competitor peptide.
|
| Animal Protocol |
REDV TFA can be tested in vivo in models of cell homing or wound healing. In a mouse model of hematopoietic stem cell transplantation, lethally irradiated mice are transplanted with bone marrow cells that have been pre-incubated with REDV TFA (100-500 ug/mL) to enhance homing to the bone marrow. After 24 h, the number of donor cells in the bone marrow is quantified by flow cytometry. The peptide is not typically administered systemically; it is used as a coating for biomaterials or in ex vivo cell treatments.
|
| ADME/Pharmacokinetics |
REDV TFA has a molecular formula of C30H44N8O12 (free base) and a molecular weight of approximately 708.72. The TFA salt form has a higher molecular weight (estimated). The peptide should be stored as a lyophilized powder at -20degC for up to 2 years, sealed and away from moisture. In solution, it is stable for 6 months at -80degC or 1 month at -20degC. It is soluble in water and DMSO. Specific PK parameters have not been reported.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data for REDV TFA are available. As a short peptide derived from a natural extracellular matrix protein, it is expected to have low inherent toxicity. Standard safety precautions for handling peptides should be followed. The compound is not intended for in vivo systemic administration and is typically used as a surface coating.
|
| References | |
| Additional Infomation |
REDV TFA is a research-grade peptide and is not approved for clinical use. It is the minimal active sequence of fibronectin that mediates cell adhesion via integrin alpha4beta1. This product is a valuable tool for studying cell adhesion, migration, and tissue engineering applications. It is for research use only.
|
| Molecular Formula |
C20H35N7O9.XC2HF3O2
|
|---|---|
| Molecular Weight |
517.53 (free acid)
|
| Related CAS # |
REDV;107978-83-6
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~100 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
